Lasa Supergenerics quarterly results and financials

Lasa Supergenerics (LASA)₹4.78−4.97%(2 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Lasa Supergenerics reported sales of −₹0.12 Cr, down 100.3% from Mar 2025, and net profit of −₹4.18 Cr. For the year to Mar 2026, sales were ₹24.93 Cr and net profit −₹34.13 Cr.

Sales (Mar 2026): −₹0.12 Cr
Net profit (Mar 2026): −₹4.18 Cr
Sales (FY Mar 2026): ₹24.93 Cr
Net profit (FY Mar 2026): −₹34.13 Cr
EPS (Mar 2026): ₹−0.82
Borrowings (Mar 2026): ₹10.04 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Lasa Supergenerics quarterly results

₹ crore unless stated; each column is a quarter.

Lasa Supergenerics Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	30.46	24.23	26.61	22.74	30.77	39.31	32.97	39.00	19.96	3.05	2.19	−0.12
Expenses	26.61	23.33	25.70	26.90	29.14	38.72	32.89	35.84	20.57	7.08	2.96	2.00
Operating Profit	4.04	1.04	1.05	−3.98	1.79	0.78	0.26	3.40	−0.49	−3.99	−0.74	−2.11
OPM %	13.2%	4.3%	4.0%	−17.5%	5.9%	2.0%	0.8%	8.7%	−2.5%	−130.7%	−34.1%	—
Other Income	0.00	0.07	0.00	−8.74	0.00	1.94	8.88	−21.47	−20.38	0.00	0.01	−0.41
Interest	0.38	0.57	0.43	0.55	0.86	1.23	0.46	0.12	0.02	0.13	0.12	0.12
Depreciation	2.66	2.69	2.69	2.67	2.80	2.82	2.81	3.91	1.58	1.58	1.58	1.32
Profit before tax	1.02	−2.10	−2.05	−15.95	−1.85	−1.30	5.90	−22.10	−22.52	−5.67	−2.40	−3.97
Tax %	580.7%	−99.0%	−29.6%	−4.2%	46.8%	146.6%	7.2%	−35.4%	−6.3%	10.1%	5.8%	4.8%
Exceptional items	0.00	0.00	0.00	−8.98	0.00	0.00	7.99	−23.96	−20.95	0.00	0.00	0.00
Net Profit	−4.97	−0.03	−1.47	−15.35	−2.74	−3.24	5.51	−14.33	−21.21	−6.27	−2.56	−4.18
EPS (Rs)	−0.98	0.00	−0.28	−3.04	−0.53	−0.63	1.09	−2.84	−4.20	−1.24	−0.50	−0.82

Lasa Supergenerics profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Lasa Supergenerics Profit and loss
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	199	243	170	166	200	137	130	104	142	24.93	25.08
Expenses	154	203	159	137	154	120	136	102	136	32.11	32.61
Operating Profit	45.97	40.94	10.99	29.98	46.99	15.97	−5.99	1.99	5.99	−6.99	−7.33
OPM %	23.0%	17.0%	7.0%	18.0%	24.0%	12.0%	−4.9%	2.1%	4.4%	−29.0%	−29.2%
Other Income	−23.93	2.99	0.00	0.00	0.00	−7.97	−17.94	−8.98	−10.98	−20.93	−20.78
Interest	11.99	11.01	8.01	7.99	2.01	0.00	3.99	1.99	3.01	0.00	0.39
Depreciation	8.03	18.04	19.05	17.06	16.03	15.05	13.03	11.03	12.04	6.02	6.06
Profit before tax	1.99	14.98	−15.98	4.99	29.97	−5.99	−41.97	−18.98	−18.98	−34.99	−34.56
Tax %	−10.0%	19.1%	−24.9%	23.1%	23.0%	−13.0%	−9.0%	14.1%	−24.0%	−2.0%	—
Exceptional items	−25.95	0.00	0.00	0.00	0.00	−7.98	−18.95	−7.99	−15.98	−20.97	−20.95
Net Profit	2.01	12.04	−12.05	4.01	23.09	−5.02	−39.15	−22.07	−15.04	−34.13	−34.22
EPS (Rs)	—	5.38	−5.24	0.88	5.58	−1.30	−7.69	−4.32	−2.94	−6.77	−6.76
Dividend payout %	0.0%	0.0%	0.0%	0.0%	4.0%	−23.9%	0.0%	0.0%	0.0%	0.0%	—

Lasa Supergenerics balance sheet

₹ crore, at each year end.

Lasa Supergenerics Balance sheet
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	0.05	0.04	22.90	22.92	40.93	40.87	49.89	49.97	49.98	49.95	50.10
Reserves	0.00	75.12	94.08	82.10	101	118	108	68.16	47.12	34.08	0.00
Borrowings	0.00	116	107	85.19	48.09	19.03	20.05	22.05	22.06	2.01	10.04
Other Liabilities	0.00	36.86	63.14	69.02	42.20	29.14	31.15	24.12	32.16	16.08	7.03
Total Liabilities	0.00	228	287	258	232	208	209	164	151	102	66.17
Fixed Assets	0.00	119	170	162	152	143	137	119	110	68.15	55.18
CWIP	0.00	29.97	6.99	6.99	0.00	0.00	5.01	4.99	3.01	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	0.00	79.95	110	89.90	79.97	64.91	66.93	39.99	38.99	32.97	10.99
Inventories	0.00	33.56	42.30	31.65	26.36	17.31	11.52	13.93	19.10	24.55	1.83
Trade receivables	0.00	34.86	41.99	28.75	20.56	14.70	18.49	2.47	3.58	1.48	0.03
Cash & equivalents	0.04	1.15	2.62	2.68	6.05	4.39	17.19	2.38	1.49	0.78	0.69
Total Assets	0.00	228	287	258	232	208	209	164	151	102	66.17

Lasa Supergenerics cash flow

₹ crore, for each year.

Lasa Supergenerics Cash flow
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	−2.99	39.92	40.93	13.97	40.89	8.97	−16.98	1.99	−2.99	—
Cash from investing activity	0.00	−43.95	−7.01	−1.99	−3.99	−2.99	10.99	0.00	8.01	—
Cash from financing activity	0.00	3.99	−32.93	−9.98	−35.90	0.00	−3.99	−1.99	−5.99	—
Net cash flow	−3.01	0.00	0.00	2.01	1.01	6.02	−10.03	0.00	0.00	—
Capex	1.68	46.53	11.29	0.62	6.57	0.00	0.00	2.31	0.00	0.00
Free cash flow	−4.98	−5.98	28.89	12.94	34.85	11.95	−11.95	0.00	4.98	—
CFO / OP %	−6.0%	103.0%	397.0%	46.0%	87.0%	73.0%	273.0%	96.0%	−45.0%	—

Lasa Supergenerics ratios

Working-capital days and returns, by year.

Lasa Supergenerics Ratios
	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	64	63	62	45	27	50	7	13	4	1
Inventory days	93	90	90	101	56	46	48	92	84	28
Days payable	70	101	169	129	40	67	31	67	34	31
Cash conversion cycle	86	50	−19	15	41	27	21	36	52	−5
Working capital days	16	0	−51	−12	36	13	−16	−43	38	−101
ROCE %	42.0%	13.0%	−4.0%	7.0%	17.0%	1.0%	−12.0%	−6.0%	−1.0%	−18.0%

Lasa Supergenerics: frequently asked questions

What are the latest quarterly results of Lasa Supergenerics?

For the Mar 2026 quarter, Lasa Supergenerics reported sales of −₹0.12 Cr, down 100.3% year on year and net profit of −₹4.18 Cr.

What is the annual revenue of Lasa Supergenerics?

Lasa Supergenerics' sales for the year to Mar 2026 were ₹24.93 Cr; over the last twelve months they were ₹25.08 Cr.

What is the net profit of Lasa Supergenerics?

Net profit for the year to Mar 2026 was −₹34.13 Cr, and −₹34.22 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−6.76.

How much debt does Lasa Supergenerics have?

Lasa Supergenerics reported borrowings of ₹10.04 Cr at Mar 2026, against cash and equivalents of ₹0.69 Cr.

What is the free cash flow of Lasa Supergenerics?

Cash from operations was −₹2.99 Cr in the year to Mar 2025; after capital spending, free cash flow was ₹4.98 Cr.

Loading…